World Bispecific Antibody Summit, September 27–28, 2011, Boston, MA

With more than 30 therapeutic monoclonal antibodies (mAbs) approved and annual global sales of the products at ~$50 billion in 2010, these products have proven to be successful in many ways. Nevertheless, there is room for improvement in performance, and substantial unmet medical needs remain. As a consequence, numerous organizations are devoting resources to engineering novel mAbs such as bispecific antibodies that have increased functionality compared with unmodified IgG molecules. The World Bispecific Antibody Summit, organized by Hanson Wade, drew over 100 participants to Boston to discuss engineering novel bispecific antibodies, generating lead candidates and clinical study and commercialization of the molecules. Approaches such as the trifunctional antibody (TRION), dual variable domain-Ig (Abbott), two-in-one (Genentech), dual affinity retargeting (MacroGenics), kappa-lambda body (NovImmune), bispecific T-cell engager (Micromet) and chemical generation (CovX/Pfizer) were discussed in detail. In addition, posters describing bispecific Affibody® molecules for targeting of EGFR and HER2 (Affibody), T-cell receptor based bi-specifics that target HLA-peptides (Immunocore), a novel mAb-Fv bispecific antibody format utilizing Fc region (Xencore), generation of a tetravalent bispecific antibody against IL4 and IL13 for the treatment of idiopathic pulmonary fibrosis (Sanofi), Combining Affibody® molecules and the Albumod™ technology to create long acting multispecific protein therapeutics (Royal Institute of Technology, Affibody) and COVA301 as a highly potent bispecific inhibitor of IL-17A and TNF-α (Covagen) were presented.

[1]  Hermann Einsele,et al.  Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  Guy Georges,et al.  Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies , 2011, Proceedings of the National Academy of Sciences.

[3]  D. Seimetz,et al.  Humoral tumor-associated immune responses induced by catumaxomab in patients with malignant ascites. , 2011, Journal of Clinical Oncology.

[4]  U. Brinkmann,et al.  Bispecific digoxigenin-binding antibodies for targeted payload delivery , 2011, Proceedings of the National Academy of Sciences.

[5]  P. Moore,et al.  Application of dual affinity retargeting molecules to achieve optimal redirected T-cell killing of B-cell lymphoma. , 2011, Blood.

[6]  R. Lerner,et al.  Chemical generation of bispecific antibodies , 2010, Proceedings of the National Academy of Sciences.

[7]  P. Moore,et al.  Therapeutic control of B cell activation via recruitment of Fcgamma receptor IIb (CD32B) inhibitory function with a novel bispecific antibody scaffold. , 2010, Arthritis and rheumatism.

[8]  P. Moore,et al.  Effector cell recruitment with novel Fv-based dual-affinity re-targeting protein leads to potent tumor cytolysis and in vivo B-cell depletion. , 2010, Journal of molecular biology.

[9]  M. Wittekind,et al.  Enhancing Antibody Fc Heterodimer Formation through Electrostatic Steering Effects , 2010, The Journal of Biological Chemistry.

[10]  J. Huston,et al.  SEEDbodies: fusion proteins based on strand-exchange engineered domain (SEED) CH3 heterodimers in an Fc analogue platform for asymmetric binders or immunofusions and bispecific antibodies. , 2010, Protein engineering, design & selection : PEDS.

[11]  D. Seimetz,et al.  Catumaxomab , 2010, mAbs.

[12]  P. Hoffmann,et al.  Mode of cytotoxic action of T cell-engaging BiTE antibody MT110. , 2009, Immunobiology.

[13]  J. Hess,et al.  The trifunctional antibody ertumaxomab destroys tumor cells that express low levels of human epidermal growth factor receptor 2. , 2009, Cancer research.

[14]  T. Barbui,et al.  Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL). , 2009, Blood.

[15]  F. Peale,et al.  Variants of the Antibody Herceptin That Interact with HER2 and VEGF at the Antigen Binding Site , 2009, Science.

[16]  T. Lebien,et al.  B lymphocytes: how they develop and function. , 2008, Blood.

[17]  H. Einsele,et al.  Tumor Regression in Cancer Patients by Very Low Doses of a T Cell–Engaging Antibody , 2008, Science.

[18]  S. Slavin,et al.  Induction of long-lasting antitumor immunity by concomitant cell therapy with allogeneic lymphocytes and trifunctional bispecific antibody. , 2008, Experimental hematology.

[19]  P. Parren,et al.  Complement-dependent tumor cell lysis triggered by combinations of epidermal growth factor receptor antibodies. , 2008, Cancer research.

[20]  I. Chaiken,et al.  Enhanced EGFR inhibition and distinct epitope recognition by EGFR antagonistic MABS C225 and 425 , 2008, Cancer biology & therapy.

[21]  P. Kufer,et al.  The effect of dexamethasone on polyclonal T cell activation and redirected target cell lysis as induced by a CD19/CD3-bispecific single-chain antibody construct , 2007, Cancer Immunology, Immunotherapy.

[22]  M. Kneba,et al.  Molecular relapse in adult standard-risk ALL patients detected by prospective MRD monitoring during and after maintenance treatment: data from the GMALL 06/99 and 07/03 trials. , 2007, Blood.

[23]  S. Slavin,et al.  Use of trifunctional bispecific antibodies to prevent graft versus host disease induced by allogeneic lymphocytes. , 2006, Blood.

[24]  P. Kufer,et al.  Induction of regular cytolytic T cell synapses by bispecific single-chain antibody constructs on MHC class I-negative tumor cells. , 2006, Molecular immunology.

[25]  P. Hoffmann,et al.  Serial killing of tumor cells by cytotoxic T cells redirected with a CD19‐/CD3‐bispecific single‐chain antibody construct , 2005, International journal of cancer.

[26]  M. Sliwkowski,et al.  An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors. , 2003, Molecular cell.

[27]  P. Hoffmann,et al.  Extremely potent, rapid and costimulation‐independent cytotoxic T‐cell response against lymphoma cells catalyzed by a single‐chain bispecific antibody , 2002, International journal of cancer.

[28]  P. Ruf,et al.  Induction of a long-lasting antitumor immunity by a trifunctional bispecific antibody. , 2001, Blood.

[29]  R. Riesenberg,et al.  Lysis of Prostate Carcinoma Cells by Trifunctional Bispecific Antibodies (αEpCAM × αCD3) , 2001 .

[30]  B. Wollenberg,et al.  The Fc-region of a new class of intact bispecific antibody mediates activation of accessory cells and NK cells and induces direct phagocytosis of tumour cells , 2000, British Journal of Cancer.

[31]  B. Wollenberg,et al.  Simultaneous activation of T cells and accessory cells by a new class of intact bispecific antibody results in efficient tumor cell killing. , 1999, Journal of immunology.

[32]  L. Presta,et al.  'Knobs-into-holes' engineering of antibody CH3 domains for heavy chain heterodimerization. , 1996, Protein engineering.

[33]  S. Thierfelder,et al.  Preferential species-restricted heavy/light chain pairing in rat/mouse quadromas. Implications for a single-step purification of bispecific antibodies. , 1995, Journal of immunology.

[34]  I. Pastan,et al.  Preparation and characterization of a disulfide-stabilized Fv fragment of the anti-Tac antibody: comparison with its single-chain analog. , 1995, Molecular immunology.

[35]  M. Bodmer,et al.  Expression, purification and characterization of a mouse-human chimeric antibody and chimeric Fab' fragment. , 1992, The Biochemical journal.

[36]  M. Tallman,et al.  In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: fin , 2006, Blood.

[37]  R. Riesenberg,et al.  Lysis of prostate carcinoma cells by trifunctional bispecific antibodies (alpha EpCAM x alpha CD3). , 2001, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.